The chart below shows how AMCR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AMCR sees a -0.26% change in stock price 10 days leading up to the earnings, and a +3.01% change 10 days following the report. On the earnings day itself, the stock moves by +0.27%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Strong Financial Performance: Our business continues to build on the momentum we've delivered since the beginning of the calendar year with another quarter of solid financial performance to kick off fiscal 2025.
Injury Reduction Success: We achieved a 13% reduction in injuries compared to the same quarter last year and 73% of our sites remaining injury-free for more than a year.
Guidance Reaffirmation Confidence: Our results are aligned with the expectations we set out in August and give us the confidence to reaffirm our guidance today.
Volume Growth Comparison: Overall volumes for the fiscal first quarter were up approximately 2% compared with 1% in Q4.
Earnings Per Share Growth: Adjusted earnings per share came in at $0.162 per share, which represents growth of 5% on a comparable constant currency basis.
Negative
Volume Growth Slowdown: Volume growth in the first quarter was only 2% compared to 1% in Q4, indicating a slowdown in growth.
Weak Health Care Volumes: Health care volumes remained weak in North America, negatively impacting overall company volumes by approximately 2%.
Net Sales Decline: Net sales decreased by 1% on a comparable constant currency basis, primarily due to continued destocking in higher-margin health care categories.
Earnings Per Share Growth: Adjusted earnings per share came in at $0.162, representing only 5% growth on a comparable constant currency basis, which is below expectations.
Volume Decline Challenges: The company experienced a 4% decline in overall volumes compared to last year, indicating challenges in maintaining growth momentum.
Amcor plc (AMCR) Q1 2025 Earnings Call Transcript
AMCR.N
1.33%